Physician

Aderonke Ajala, MD

According to 2025 Medicare claims, Aderonke Ajala, MD (NPI: 1689015042) practices hematology/oncology in the State College, PA market, with the plurality of this provider's patient population coming from Centre, PA. This provider's primary affiliated billing organization is CENTRE COUNTY CANCER CENTER (NPI: 1477891711; TIN: 800866636) and primary practice location at 16803-6701.

Ajala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 499 traditional Medicare patients, billed 219,869 HCPCS/CPT codes, and received $3,442,504 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,070 prescription claims across 336 beneficiaries totaling $4,483,182 in drug costs, led by Ibrance (Palbociclib). DME data shows 27 claims. Open Payments data shows 17 records totaling $355. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $58,287 to $3,442,504. Similarly, Part D prescription costs have risen steadily, from $7,239 to $4,483,182. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	261	903	$58,287
2021	336	12,934	$288,464
2022	402	145,933	$2,596,905
2023	427	142,751	$2,033,234
2024	499	219,869	$3,442,504

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	25	170	$7,239
2016	27	109	$9,616
2017	17	50	$2,737
2018	12	24	$751
2019	N/R	16	$250
2020	143	738	$1,251,514
2021	159	673	$1,775,971
2022	285	1,448	$2,522,936
2023	330	1,965	$3,393,420
2024	336	2,070	$4,483,182

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	45	$2,235
2023	N/R	71	$23,094
2024	N/R	27	$762

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	67	67	$162
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	131	342	$144
96413	Administration of chemotherapy into vein, 1 hour or less	100	441	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	188	245	$96
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	86	219	$47

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	37	1,036	$592,689
Revlimid	Lenalidomide	26	672	$538,125
Xtandi	Enzalutamide	29	870	$392,491
Brukinsa	Zanubrutinib	26	780	$373,771
Pemazyre	Pemigatinib	16	336	$338,554

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$587
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	15	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$355	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aderonke Ajala, MD?

Tedicare shows public-source Medicare data for Aderonke Ajala, MD (NPI 1689015042), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aderonke Ajala, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Aderonke Ajala, MD?

Aderonke Ajala, MD is linked to CENTRE COUNTY CANCER CENTER (billing NPI 1477891711) in the available physician profile data.

Does Aderonke Ajala, MD have Open Payments data?

Aderonke Ajala, MD has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.